吡柔比星用于乳腺癌术后新辅助化疗的安全性和有效性分析

Safety and efficacy of neoadjuvant chemotherapy with Pirarubicin for breast cancer after surgery

目的探讨以吡柔比星为主的化疗方案应用于乳腺癌治疗的安全和有效性。方法将本院2011年1月—2012年6月诊治的96例局部晚期乳腺癌患者随机分成两组:对照组48例,采用多柔比星为主的新辅助化疗方案;试验组48例,采用吡柔比星为主的新辅助化疗方案。观察和比较两组的化疗效果和不良反应。结果试验组和对照组的总缓解率分别为81.25%、77.08%,两组疗效比较差异无统计学意义(P>0.05);试验组的心脏毒性、脱发的发生率分别为16.67%、39.58%,对照组的心脏毒性、脱发的发生率分别为35.42%、77.08%,试验组的心脏毒性、脱发的发生率明显低于对照组(P<0.05)。结论毗柔比星联合化疗治疗局部晚期乳腺癌比多柔比星更安全可靠。

Objective To investigate the safety and the clinical efficacy of neoadjuvant chemotherapy with Pirarubicin for breast cancer after surgery. Methods A total of 96 cases of locally advanced breast cancer patients admitted to hospital from January 2011 to June 2012 were divided into two groups at random, i.e. control group （n = 48） and trial group （n = 48）. The control group was given neoadjuvant chemotherapy with Doxorubicin, and the trial group with Pirarubicin. The clinical efficacy and the ad- verse reactions were observed and compared between the two groups. Results The total remission rate was 81.25% in the trial group and 77.08% in the control group, between which there was no statistically significant difference （ P 〉 0.05）. The incidence of cardiotoxieity was 16.67% vs. 35.42% （trial group vs. control group） , and that of alopecia was 39.58% vs. 77.08%. The adverse reactions of the trial group were significantly lower than that of the control group （P 〈 0.05）. Conclusion Pirarubicin, acting as a neoadjuvant chemotherapy for locally advanced breast cancer, is safe and reliable.